Journal article icon

Journal article

Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial

Abstract:

Background Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG trial, we showed that homocysteine-lowering treatment with B vitamins slows the rate of brain atrophy in mild cognitive impairment (MCI). Here we report the effect of B vitamins on cognitive and clinical decline (secondary outcomes) in the same study. Methods This was a double-blind, single-centre study, which included participants with MCI, aged ≥70y, randomly assigned to receive a daily dose...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/gps.2758

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Role:
Author
Publisher:
Wiley Publisher's website
Journal:
International Journal of Geriatric Psychiatry Journal website
Volume:
27
Issue:
6
Pages:
592-600
Publication date:
2012-06-01
Acceptance date:
2011-05-16
DOI:
EISSN:
1099-1166
ISSN:
0885-6230
Pmid:
21780182
Source identifiers:
325879
Keywords:
Pubs id:
pubs:325879
UUID:
uuid:7c08c1fd-c80d-44f6-b640-9a478a1f453b
Local pid:
pubs:325879
Deposit date:
2016-12-18

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP